Pediatrik Epilepsi İçin İlaç Rehberi

Arya R, Shinnar S, Glauser TA. Corticosteroids for the Treatment of Infantile Spasms: A Systematic Review. [cited 2024 Feb 11]; Available from: http://jcn.sagepub.com

Hollenshead PP, Jackson CN, Cross J V, Taylor ·, Witten E, Ahmed ·, et al. Treatment modalities for infantile spasms: current considerations and evolving strategies in clinical practice. Neurological Sciences [Internet]. 2024 [cited 2024 Feb 11];45:507–14. Available from: https://doi.org/10.1007/s10072-023-07078-z

Riikonen R. Topical Review Infantile Spasms: Outcome in Clinical Studies. 2020 [cited 2024 Feb 11]; Available from: https://doi.org/10.1016/j.pediatrneurol.2020.01.015

Jain P, Sahu JK, Horn PS, Chau V, Go C, Mahood Q, et al. Treatment of children with infantile spasms: A network meta-analysis. Dev Med Child Neurol. 2022;64:1330–43.

Hancı F, Canpolat M, Kumandaş S. West Sendromu. In: Kumadaş Canpolat, editor. Temel Pediatrik Nöroloji, Tanı ve Tedavi. 1st ed. Akademisyen Kitabevi; 2022. p. 2217–28.

Cosyntropin (tetracosactide): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 13]. Available from: https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/print?search=synacthen&source=panel_search_result&selectedTitle=2~110&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Lai YC, Muscal E, Wells E, Shukla N, Eschbach K, Hyeong Lee K, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020;7:2467–74.

Kenney-Jung DL, Kahoud RJ, Vezzani A, Lafrance-Corey RG, Ho ML, Muskardin TW, et al. Super-refractory status epilepticus and febrile infection-related epilepsy syndrome treated with anakinra. [cited 2024 Feb 11]; Available from: www.mayomedicallaboratories.com/test-catalog/Overview/61511

Van Baalen A. Febrile infection-related epilepsy syndrome in childhood: A clinical review and practical approach. Seizure: European Journal of Epilepsy [Internet]. 2023 [cited 2024 Feb 11];111:1059–311. Available from: http://creativecommons.org/licenses/by/4.0/

Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus including febrile infection-related epilepsy syndrome: Statements and supporting evidence. Epilepsia. 2022;63:2840–64.

Rn Kullenberg T, Lö Fqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. [cited 2024 Feb 11]; Available from: https://academic.oup.com/rheumatology/article/55/8/1499/2566682

Anakinra: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 13]. Available from: https://www.uptodate.com/contents/anakinra-pediatric-drug-information/print?search=anakinra&source=panel_search_result&selectedTitle=2~129&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Meissner H, Cascella M. Cannabidiol (CBD). StatPearls [Internet]. 2023 [cited 2024 Feb 4]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK556048/

Cannabidiol (pharmaceutical): Pediatric drug information - UpToDate [Internet]. Available from: https://www.uptodate.com/contents/cannabidiol-pharmaceutical-pediatric-drug-information/print?search=cannabidiol&source=panel_search_result&selectedTitle=2~62&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Carlsbad CA. Epidiolex (cannabidiol) [prescribing information]. Greenwich Biosciences Inc. 2021;

Verlag K, Heinen F. NeuroKids Child Neurology Workbook: Diagnosis and Therapy. Mind Maps, Germany: W Kohlhammer GMbH Stuttgart. 2017;391–555.

Custer JW. et al. The Harriet lane handbook: mobile medicine series-expert consult. Elsevier Health Sciences; 2009. 717–1030 p.

Diazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 4]. Available from: https://www.uptodate.com/contents/diazepam-pediatric-drug-information/print?search=diazepam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. J Pain Symptom Manage. 2014;47:955–64.

Kienitz R, Kay L, Beuchat I, Gelhard S, Von Brauchitsch S, Mann · Catrin, et al. Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability Graphical Abstract Benzodiazepines in the management of seizures and status epileppcus: a review of routes of delivery, pharmacokineecs, efficacy, and tolerability. CNS Drugs [Internet]. 123AD [cited 2024 Feb 5];36. Available from: https://doi.org/10.1007/s40263-022-00940-2

Ethosuximide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 4]. Available from: https://www.uptodate.com/contents/ethosuximide-pediatric-drug-information/print?search=etos%C3%BCksimid&source=panel_search_result&selectedTitle=2~21&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, Valproic Acid and Lamotrigine in Childhood Absence Epilepsy: Initial Monotherapy Outcomes at 12 months. Epilepsia [Internet]. 2013 [cited 2024 Feb 4];54:141. Available from: /pmc/articles/PMC3538883/

Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr [Internet]. 2016 [cited 2024 Feb 5];16:48. Available from: /pmc/articles/PMC4749120/

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. The Lancet [Internet]. 2013 [cited 2024 Feb 5];381:125–32. Available from: http://www.thelancet.com/article/S0140673612611349/fulltext

Everolimus: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/everolimus-pediatric-drug-information?search=everolimus&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Felbamate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/felbamate-pediatric-drug-information?search=felbamat&source=panel_search_result&selectedTitle=2~22&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit [Internet]. 2018 [cited 2024 Feb 5];40:526–48. Available from: https://journals.lww.com/drug-monitoring/fulltext/2018/10000/therapeutic_drug_monitoring_of_antiepileptic_drugs.2.aspx

Phenytoin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/print?search=fenitoin&selectedTitle=1~147&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocritical Care 2012 17:1 [Internet]. 2012 [cited 2024 Feb 5];17:3–23. Available from: https://link.springer.com/article/10.1007/s12028-012-9695-z

Guerrini R. Epilepsy in children. The Lancet [Internet]. 2006 [cited 2024 Feb 5];367:499–524. Available from: http://www.thelancet.com/article/S0140673606681828/fulltext

Chaves J, Sander JW, Sander L. Seizure Aggravation in Idiopathic Generalized Epilepsies. Epilepsia [Internet]. 2005 [cited 2024 Feb 5];46:133–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2005.00325.x

Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. Pediatrics [Internet]. 2008 [cited 2024 Feb 5];122:398–417. Available from: /pediatrics/article/122/2/398/73042/Vitamin-D-Deficiency-in-Children-and-Its

Wagner CL, Greer FR. Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents the Section on Breastfeeding and Committee on Nutrition. Pediatrics [Internet]. 2008 [cited 2024 Feb 5];122:1142–52. Available from: www.pediatrics.org/cgi/doi/10.1542/

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. Journal of Pediatrics [Internet]. 2001 [cited 2024 Feb 5];139:317–9. Available from: http://www.jpeds.com/article/S002234760118950X/fulltext

Zar T, Graeber C, Perazella MA. Reviews: Recognition, Treatment, and Prevention of Propylene Glycol Toxicity. Semin Dial [Internet]. 2007 [cited 2024 Feb 5];20:217–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1525-139X.2007.00280.x

Chandrasekaran S, Patil S, Suthar R, Attri SV, Sahu JK, Sankhyan N, et al. Hyperhomocysteinaemia in children receiving phenytoin and carbamazepine monotherapy: a cross-sectional observational study. Arch Dis Child [Internet]. 2017 [cited 2024 Feb 5];102:346–51. Available from: https://adc.bmj.com/content/102/4/346

Fosphenytoin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 10]. Available from: https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/print?search=fosfenitoin&source=panel_search_result&selectedTitle=2~50&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Morton LD. Clinical experience with fosphenytoin in children. J Child Neurol. 1998;13.

Shenoi RP, Timm N, Jones B, Neville K, Foster J, Houck C, et al. Drugs used to treat pediatric emergencies. Pediatrics [Internet]. 2020 [cited 2024 Feb 11];145:288–92. Available from: /pediatrics/article/145/1/e20193450/36970/Drugs-Used-to-Treat-Pediatric-Emergencies

Phenobarbital: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/phenobarbital-pediatric-drug-information/print?search=fenobarbital&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Vasquez A, Gaínza-Lein M, Sánchez Fernández I, Abend NS, Anderson A, Brenton JN, et al. Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research Centers. Pediatr Neurol [Internet]. 2018 [cited 2024 Feb 5];86:33–41. Available from: http://www.pedneur.com/article/S0887899418302315/fulltext

Tobias JD. Pentobarbital for Sedation During Mechanical Ventilation in the Pediatric ICU Patient. 2000.

Fenfluramine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/print?search=fenfluramine&source=panel_search_result&selectedTitle=2~22&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Wirrell EC. Treatment of Dravet Syndrome. Canadian Journal of Neurological Sciences. 2016;43:S13–8.

Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatr Neurol [Internet]. 2017 [cited 2024 Feb 5];68:18-34.e3. Available from: http://www.pedneur.com/article/S0887899416310372/fulltext

Gabapentin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/print?search=gabapentin&selectedTitle=1~146&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Beauvais K, Disson-Dautriche A, Jacquin A, Antoniol C, Martin ML. Gabapentin-induced encephalopathy. Clinical Neurophysiology. 2015;126:845–6.

Hui CH, Ka-Chun Leung J, Shek-Kwan Chang R, Shea YF. Reversible dysphagia due to gabapentin-induced jaw myoclonus. 2019 [cited 2024 Feb 5]; Available from: www.cmj.org

Bilgir O, Alan M, Bilgir F, Kebapılar L, Yksel A, Ar Yıldız Y", et al. Gabapentin-Induced Rhabdomyolysis in a Patient with Diabetic Neuropathy. [cited 2024 Feb 5]; Available from: http://www.naika.or.jp/imindex.html

Choi MS, Jeon H, Kim HS, Jang BH, Lee YH, Park HS, et al. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodialysis International [Internet]. 2017 [cited 2024 Feb 5];21:E4–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/hdi.12458

Hampton Z, Shahrestani N, Little A. Gabapentin-induced Facial Myoclonus in the Setting of Acute on Chronic Kidney Disease. [cited 2024 Feb 5]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s050,020882s035,021129s033lbl.pdf

Parsons KA, Derkits ME. Visual hallucinations associated with gabapentin use. American Journal of Health-System Pharmacy [Internet]. 2016 [cited 2024 Feb 5];73:631–4. Available from: https://dx.doi.org/10.2146/ajhp150136

Rohman L, Hebron A. Acute dystonic reaction caused by gabapentin. Journal of Emergency Medicine [Internet]. 2014 [cited 2024 Feb 5];46:e89. Available from: http://www.jem-journal.com/article/S0736467913009347/fulltext

Souzdalnitski D, Chang AK, Guirguis M. Chorea in a Chronic Pain Patient Using Gabapentin. Ochsner J [Internet]. 2014 [cited 2024 Feb 5];14:276. Available from: /pmc/articles/PMC4052599/

Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. European Neuropsychopharmacology. 2017;27:1185–215.

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) | FDA [Internet]. [cited 2024 Feb 9]. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin

Norton JW, Professor of Neurology A. Gabapentin Withdrawal Syndrome [Internet]. Vol. 24, Clinical Neuropharmacology. 2001. Available from: http://journals.lww.com/clinicalneuropharmbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo

Immune globulin (Intravenous, subcutaneous, and intramuscular): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/print?search=imm%C3%BCn%20globulin%20intraven%C3%B6z&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA [Internet]. 2021 [cited 2024 Feb 6];325:855–64. Available from: https://jamanetwork.com/journals/jama/fullarticle/2776054

Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P, et al. Challenges in the treatment of convulsive status epilepticus. 2017 [cited 2024 Feb 11]; Available from: http://dx.doi.org/10.1016/j.seizure.2017.02.015

Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9.

Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–77.

Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia. 2015;56:915–23.

Bertilsson L. Clinical Pharmacokinetics of Carbamazepine. Clin Pharmacokinet. 1978;3:128–43.

Carbamazepine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/print?search=karbamazepin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Tutor-Crespo MJ, Hermida J, Tutor JC. Relative Proportions of Serum Carbamazepine and its Pharmacologically Active 10,11-Epoxy Derivative: Effect of Polytherapy and Renal Insufficiency. Ups J Med Sci [Internet]. 2008 [cited 2024 Feb 12];113:171–80. Available from: https://www.tandfonline.com/doi/abs/10.3109/2000-1967-225

Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions. Neurology [Internet]. 2017 [cited 2024 Feb 12];88:2183. Available from: /pmc/articles/PMC5467955/

Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clin Pharmacol Ther [Internet]. 2013 [cited 2024 Feb 12];94:324. Available from: /pmc/articles/PMC3748365/

Godwin SA, Burton JH, Gerardo CJ, Hatten BW, MacE SE, Silvers SM, et al. Clinical Policy: Procedural Sedation and Analgesia in the Emergency Department. Ann Emerg Med [Internet]. 2014 [cited 2024 Feb 5];63:247-258.e18. Available from: http://www.annemergmed.com/article/S0196064413014893/fulltext

Green SM, Roback MG, Kennedy RM, Krauss B. Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update. Ann Emerg Med [Internet]. 2011 [cited 2024 Feb 5];57:449–61. Available from: http://www.annemergmed.com/article/S0196064410018275/fulltext

Ferguson CL, Beckett RD. Intranasal ketamine for treatment of acute pain in pediatrics: A systematic review. Pediatr Emerg Care [Internet]. 2020 [cited 2024 Feb 5];36:476–81. Available from: https://journals.lww.com/pec-online/fulltext/2020/08000/intranasal_ketamine_for_treatment_of_acute_pain_in.22.aspx

Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial. JAMA Pediatr [Internet]. 2019 [cited 2024 Feb 5];173:140. Available from: /pmc/articles/PMC6439599/

Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for pediatric sedation. Pediatr Emerg Care. 2012;28:1391–8.

Ketamine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/ketamine-pediatric-drug-information?search=ketamin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine*. J Pain Symptom Manage [Internet]. 2015 [cited 2024 Feb 5];50:268–78. Available from: http://www.jpsmjournal.com/article/S0885392415002729/fulltext

Isojarvi J, Gidal BE, Chung S, Wechsler RT. Optimizing clobazam treatment in patients with Lennox–Gastaut syndrome. Epilepsy and Behavior [Internet]. 2018 [cited 2024 Feb 5];78:149–54. Available from: http://www.epilepsybehavior.com/article/S1525505017307217/fulltext

Perry MS, Bailey L, Malik S, Gilson C, Kotecha A, Hernandez A. Clobazam for the treatment of intractable epilepsy in children. J Child Neurol [Internet]. 2013 [cited 2024 Feb 5];28:34–9. Available from: https://journals.sagepub.com/doi/10.1177/0883073812461943?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Clobazam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/clobazam-pediatric-drug-information/print?search=klobazam&source=panel_search_result&selectedTitle=2~27&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kamas T, Serdaro E, Yılmaz O, Aydın Kılıç B, Polat BG, Erdo I, et al. The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. Epilepsy Res [Internet]. 2022 [cited 2024 Feb 5];184:106963. Available from: https://doi.org/10.1016/j.eplepsyres.2022.106963

Ng Y tze, Collins SD. Clobazam. Neurotherapeutics [Internet]. 2007 [cited 2024 Feb 5];4:138. Available from: /pmc/articles/PMC7479695/

Clonazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/print?search=klonazepam&usage_type=panel&kp_tab=drug_pediatric&source=panel_search_result&selectedTitle=2~131&display_rank=1

Lamotrigine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information?search=lamotrijin&source=panel_search_result&selectedTitle=2~139&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

French JA, Perucca E, Sander JW, Bergfeldt L, Baulac M, Auerbach DS, et al. FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsia Open [Internet]. 2021 [cited 2024 Feb 6];6:45. Available from: /pmc/articles/PMC7918301/

Lacosamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/lacosamide-pediatric-drug-information?search=lakozamid&source=panel_search_result&selectedTitle=2~35&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia [Internet]. 2017 [cited 2024 Feb 6];58:933–50. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13716

Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, et al. Lacosamide in pediatric and adult patients: Comparison of efficacy and safety. [cited 2024 Feb 6]; Available from: http://dx.doi.org/10.1016/j.seizure.2012.12.009

Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia. 2010;51:958–67.

Newey CR, Le NM, Ahrens C, Sahota P, Hantus S. The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill. Neurocrit Care [Internet]. 2017 [cited 2024 Feb 6];26:273–9. Available from: https://link.springer.com/article/10.1007/s12028-016-0322-2

Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, Smeyers-Durá P, Herranz-Fernández JL, Ibáñez-Micó S, et al. Efficacy and Tolerability of Lacosamide in the Concomitant Treatment of 130 Patients Under 16 Years of Age with Refractory Epilepsy: A Prospective, Open-Label, Observational, Multicenter Study in Spain. Drugs R D [Internet]. 2012 [cited 2024 Feb 6];12:187. Available from: /pmc/articles/PMC3585895/

Levetiracetam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information?search=levetirasetam&source=panel_search_result&selectedTitle=2~115&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kochanek PM, Tasker RC, Carney N, Totten AM, Adelson PD, Selden NR, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary. Clin Neurosurg [Internet]. 2019 [cited 2024 Feb 6];84:1169–78. Available from: https://journals.lww.com/neurosurgery/fulltext/2019/06000/guidelines_for_the_management_of_pediatric_severe.2.aspx

Chau K, Yong J, Ismail K, Griffith N, Liu M, Makris A. Levetiracetam-induced severe acute granulomatous interstitial nephritis. Clin Kidney J [Internet]. 2012 [cited 2024 Feb 6];5:234. Available from: /pmc/articles/PMC4400501/

Kim J, Shin JW. Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. Epileptic Disorders [Internet]. 2017 [cited 2024 Feb 6];19:104–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1684/epd.2017.0889

Bonastre MTT, Muñoz SP, Boza FM, Gumà Padró J. Neutropenia Secondary to Exposure to Levetiracetam. https://doi.org/105301/tj5000312 [Internet]. 2015 [cited 2024 Feb 6];101:e145–6. Available from: https://journals.sagepub.com/doi/10.5301/tj.5000312?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Yim SH, Choi YH, Heo K, Cho KH. A case of dyskinesia after levetiracetam administration. BMC Neurol [Internet]. 2019 [cited 2024 Feb 6];19. Available from: /pmc/articles/PMC6862831/

Lee YY, Ko JH, Chung WH. Acute generalized exanthematous pustulosis induced by levetiracetam. Int J Dermatol. 2014;53.

Bayram AK, Canpolat M, Çinar SL, Tahan F, Gumus H, Kumandaş S, et al. Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient. Journal of Emergency Medicine [Internet]. 2016 [cited 2024 Feb 6];50:e61–6. Available from: http://www.jem-journal.com/article/S0736467915010525/fulltext

Jayashankar S, Munakomi S, Sayeerajan V, Kafle P, Chaudhary P, Thingujam J, et al. Open Peer Review Case Report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient [version 1; peer review: 2 approved]. 2019 [cited 2024 Feb 6]; Available from: https://doi.org/10.12688/f1000research.18198.1

Van Den Broek MPH, Rademaker CMA, Van Straaten HLM, Huitema ADR, Toet MC, De Vries LS, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed [Internet]. 2013 [cited 2024 Feb 6];98:F341–5. Available from: https://fn.bmj.com/content/98/4/F341

Malingré MM, Van Rooij LGM, Rademaker CMA, Toet MC, Ververs TFFT, Van Kesteren C, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr [Internet]. 2006 [cited 2024 Feb 6];165:598–604. Available from: https://link.springer.com/article/10.1007/s00431-006-0136-x

Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-pediatric-drug-information/print?search=lidokain&selectedTitle=1~125&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Favié LMA, Huitema ADR, van den Broek MPH, Rademaker CMA, de Haan TR, van Straaten HLM, et al. Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen. Br J Clin Pharmacol. 2020;86:75–84.

Weeke LC, Toet MC, Van Rooij LGM, Groenendaal F, Boylan GB, Pressler RM, et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. Epilepsia [Internet]. 2016 [cited 2024 Feb 6];57:233–42. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13286

Pressler RM, Abend NS, Auvin S, Boylan G, Brigo F, Cilio MR, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations—Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia. 2023;64:2550–70.

Lorazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/print?search=lorazepam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Methylprednisolone: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/print?search=metilprednizolon&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Early Acute Management in Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionals. J Spinal Cord Med [Internet]. 2008 [cited 2024 Feb 6];31:403. Available from: /pmc/articles/PMC2582434/

Johannesdottir SA, Horváth-Puh́o E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med [Internet]. 2013 [cited 2024 Feb 6];173:743–52. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1673744

Midazolam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 7]. Available from: https://www.uptodate.com/contents/midazolam-pediatric-drug-information/print?search=midazolam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Mula M. The safety and tolerability of intranasal midazolam in epilepsy. Expert Rev Neurother. 2014;14:735–40.

Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42:380–6.

van der Vossen AC, van Nuland M, Ista EG, de Wildt SN, Hanff LM. Oral lorazepam can be substituted for intravenous midazolam when weaning paediatric intensive care patients off sedation. Acta Paediatr [Internet]. 2018 [cited 2024 Feb 9];107:1594. Available from: /pmc/articles/PMC6120549/

Mayel M, Nejad MA, Khabaz MS, Bazrafshani MS, Mohajeri E. Intranasal midazolam sedation as an effective sedation route in pediatric patients for radiologic imaging in the emergency ward: A single-blind randomized trial. Turk J Emerg Med [Internet]. 2020 [cited 2024 Feb 9];20:168. Available from: /pmc/articles/PMC7549517/

Warrington SE, Collier HK, Himebauch AS, Wolfe HA. Evaluation of IV to enteral benzodiazepine conversion calculations in a pediatric intensive care setting. Pediatric Critical Care Medicine [Internet]. 2018 [cited 2024 Feb 9];19:E569–75. Available from: https://journals.lww.com/pccmjournal/fulltext/2018/11000/evaluation_of_iv_to_enteral_benzodiazepine.19.aspx

Fantacci C, Fabrizio GC, Ferrara P, Franceschi F, Chiaretti A. IN drug administration for procedural sedation in children admitted to Pediatric Emergency Room.

Ancora G, Lago P, Garetti E, Merazzi D, Savant Levet P, Bellieni CV, et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. Acta Paediatr [Internet]. 2019 [cited 2024 Feb 9];108:208–17. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/apa.14606

Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit [Internet]. 2000. Available from: http://journals.lww.com/ccmjournal

Oxcarbazepine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/print?search=okskarbazepin&source=panel_search_result&selectedTitle=2~126&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Martinez W, Ingenito A, Blakeslee M, Barkley GL, McCague K, D’Souza J. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy and Behavior. 2006;9:448–56.

Buggy Y, Layton D, Fogg C, Shakir SAW. Safety profile of oxcarbazepine: Results from a prescription-event monitoring study. Epilepsia. 2010;51:818–29.

Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol [Internet]. 2005 [cited 2024 Feb 9];33:337–44. Available from: http://www.pedneur.com/article/S0887899405002687/fulltext

Piña-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65:1370–5.

Kothare S V., Mostofi N, Khurana DS, Mohsem B, Melvin JJ, Hardison HH, et al. Oxcarbazepine Therapy in Very Young Children: A Single-Center Clinical Experience. Pediatr Neurol [Internet]. 2006 [cited 2024 Feb 9];35:173–6. Available from: http://www.pedneur.com/article/S0887899406001883/fulltext

Berghuis B, van der Palen J, de Haan GJ, Lindhout D, Koeleman BPC, Sander JW, et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017;58:1227–33.

Piracetam: International drug information (concise) - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/piracetam-international-drug-information-concise/print?search=pirasetam&source=panel_search_result&selectedTitle=1~9&usage_type=panel&kp_tab=drug_international&display_rank=1

Dai AI, Demiryürek AT. Effectiveness Oral Theophylline, Piracetam, and Iron Treatments in Children With Simple Breath-Holding Spells. J Child Neurol [Internet]. 2020 [cited 2024 Feb 9];35:25–30. Available from: https://journals.sagepub.com/doi/10.1177/0883073819871854?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Sawires H, Botrous O. Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells. Eur J Pediatr [Internet]. 2012 [cited 2024 Feb 9];171:1063–7. Available from: https://link.springer.com/article/10.1007/s00431-012-1680-1

Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical Practice Guideline: Bell’s Palsy. Otolaryngology–Head and Neck Surgery [Internet]. 2013 [cited 2024 Feb 9];149:S1–27. Available from: https://onlinelibrary.wiley.com/doi/full/10.1177/0194599813505967

Yoo HW, Yoon L, Kim HY, Kwak MJ, Park KH, Bae MH, et al. Comparison of conservative therapy and steroid therapy for Bell’s palsy in children. Korean J Pediatr [Internet]. 2018 [cited 2024 Feb 9];61:332. Available from: /pmc/articles/PMC6212712/

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology [Internet]. 2021 [cited 2024 Feb 9];96:114. Available from: /pmc/articles/PMC7884987/

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev [Internet]. 2016 [cited 2024 Feb 9];2016. Available from: /pmc/articles/PMC8580515/

Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology [Internet]. 2016 [cited 2024 Feb 9];86:465. Available from: /pmc/articles/PMC4773944/

Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014;122:455–64.

Prednisolone (systemic): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/prednisolone-systemic-pediatric-drug-information/print?search=prednizolon&source=panel_search_result&selectedTitle=2~145&usage_type=panel&showDrugLabel=true&display_rank=2

Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4.

Pregabalin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/pregabalin-pediatric-drug-information/print?search=pregabalin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J [Internet]. 2016 [cited 2024 Feb 9];14. Available from: /pmc/articles/PMC4967327/

Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, et al. Practice parameter: Therapies for essential tremor: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008–20.

Primidone: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/primidone-pediatric-drug-information/print?search=primidon&source=panel_search_result&selectedTitle=2~52&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology 2012 260:3 [Internet]. 2012 [cited 2024 Feb 9];260:714–40. Available from: https://link.springer.com/article/10.1007/s00415-012-6628-x

Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10:148–61.

Propofol: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/propofol-pediatric-drug-information/print?search=propofol&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Prabhakar H, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev [Internet]. 2017 [cited 2024 Feb 9];2017. Available from: /pmc/articles/PMC6464235/

Vespasiano M, Finkelstein M, Kurachek S. Propofol Sedation: Intensivists’ Experience With 7304 Cases in a Children’s Hospital. Pediatrics [Internet]. 2007 [cited 2024 Feb 9];120:e1411–7. Available from: /pediatrics/article/120/6/e1411/70538/Propofol-Sedation-Intensivists-Experience-With

Srinivasan M, Turmelle M, Depalma LM, Mao J, Carlson DW. Procedural Sedation for Diagnostic Imaging in Children by Pediatric Hospitalists using Propofol: Analysis of the Nature, Frequency, and Predictors of Adverse Events and Interventions. J Pediatr. 2012;160:801-806.e1.

Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med [Internet]. 2013 [cited 2024 Feb 9];41:263–306. Available from: https://journals.lww.com/ccmjournal/fulltext/2013/01000/clinical_practice_guidelines_for_the_management_of.29.aspx

Holtkamp M. Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults. Drugs [Internet]. 2018 [cited 2024 Feb 9];78. Available from: https://doi.org/10.1007/s40265-017-0859-1

Pyridoxine-Dependent Epilepsy - Symptoms, Causes, Treatment | NORD [Internet]. [cited 2024 Feb 9]. Available from: https://rarediseases.org/rare-diseases/pyridoxine-dependent-epilepsy/

Coughlin CR, Tseng LA, Abdenur JE, Ashmore C, Boemer F, Bok LA, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2021;44:178–92.

Stockler S, Plecko B, Gospe SM, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104:48–60.

Vitamin B6 (pyridoxine): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/print?search=pridoksin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Morrow LE, Wear RE, Schuller D, Malesker M. Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [Internet]. 2006 [cited 2024 Feb 9];26:1529–32. Available from: https://onlinelibrary.wiley.com/doi/full/10.1592/phco.26.10.1529

Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand [Internet]. 2016 [cited 2024 Feb 12];133:160. Available from: /pmc/articles/PMC4738453/

Yamamoto T, Gil-Nagel A, Wheless JW, Kim JH, Wechsler RT. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence. Vol. 136, Epilepsy and Behavior. Academic Press Inc.; 2022.

Perampanel: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/perampanel-pediatric-drug-information/print?search=perampanel&source=panel_search_result&selectedTitle=2~18&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nepal G, Shing YK, Yadav JK, Rehrig JH, Ojha R, Huang DY, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis. Acta Neurol Scand [Internet]. 2020 [cited 2024 Feb 13];142:449–59. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ane.13291

Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol [Internet]. 2016 [cited 2024 Feb 13];73:1342–8. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2553834

Rituximab (intravenous) including biosimilars: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/print?search=rituximab&selectedTitle=1~147&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88.

Rufinamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/rufinamide-pediatric-drug-information/print?search=rufinamid&source=panel_search_result&selectedTitle=2~9&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kluger G, Haberlandt E, Kurlemann G, Ernst JP, Runge U, Schneider F, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy & Behavior. 2010;17:546–8.

Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia. 2009;50:1899–909.

Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia [Internet]. 2011 [cited 2024 Feb 9];52:234–42. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2010.02729.x

Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs [Internet]. 2021 [cited 2024 Feb 12];35:935. Available from: /pmc/articles/PMC8408078/

Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer [Internet]. 2011 [cited 2024 Feb 9];57:1018–24. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.23124

Sun B, Han T, Wang Y, Gao Q, Cui J, Shen W. Sirolimus as a Potential Treatment for Sturge-Weber Syndrome. Journal of Craniofacial Surgery [Internet]. 2021 [cited 2024 Feb 9];32:257–60. Available from: https://journals.lww.com/jcraniofacialsurgery/fulltext/2021/02000/sirolimus_as_a_potential_treatment_for.60.aspx

Sirolimus (conventional): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/sirolimus-conventional-pediatric-drug-information/print?search=sirolimus&selectedTitle=1~145&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Stiripentol: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/stiripentol-pediatric-drug-information/print?search=stiripentol&source=panel_search_result&selectedTitle=2~12&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Fisher JL. The anticonvulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology [Internet]. 2009 [cited 2024 Feb 9];56:190. Available from: /pmc/articles/PMC2665930/

Chiron C, Marchand MC, Tran A, Rey E, D’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. Lancet [Internet]. 2000 [cited 2024 Feb 9];356:1638–42. Available from: http://www.thelancet.com/article/S0140673600031573/fulltext

Milburn-McNulty P, Panebianco M, Marson AG. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev [Internet]. 2021 [cited 2024 Feb 9];2021. Available from: /pmc/articles/PMC8459749/

Tacke M, Borggraefe I, Gerstl L, Heinen F, Vill K, Bonfert M, et al. Effects of Levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: A randomized controlled trial. Seizure. 2018;56:115–20.

Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo-controlled study. Epilepsia. 2000;41:1284–8.

Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249–51.

Tiagabine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/tiagabine-pediatric-drug-information/print?search=tiagabin&source=panel_search_result&selectedTitle=1~26&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Uthman BM, Rowan AJ, Ahmann PA, Leppik IE, Schachter SC, Sommerville KW, et al. Tiagabine for complex partial seizures: A randomized, add-on, dose- response trial. Arch Neurol. 1998;55:56–62.

Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84:940–5.

Cantarín-Extremera V, Jiménez-Legido M, Duat-Rodríguez A, García-Fernández M, Valentina Ortiz-Cabrera N, Luz Ruiz-Falcó-Rojas M, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients. 2020 [cited 2024 Feb 11]; Available from: https://doi.org/10.1016/j.jneuroim.2019.577142

Stredny CM, Case S, Sansevere AJ, Son M, Henderson L, Gorman MP. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). [cited 2024 Feb 11]; Available from: https://us.sagepub.com/en-us/nam/open-access-at-sage

Girardin ML, Flamand T, Roignot O, Abi Warde MT, Mutschler V, Voulleminot P, et al. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia. 2023;64:e87–92.

Tocilizumab (including biosimilars): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/tocilizumab-including-biosimilars-pediatric-drug-information/print?search=tocilizumab&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Leung E, Crass RL, J Jorgensen SC, Raybardhan S, Langford BJ, Justin Moore W, et al. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin Pharmacokinet [Internet]. 123AD [cited 2024 Feb 11];61:11. Available from: https://doi.org/10.1007/s40262-021-01092-0

Topiramate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/topiramate-pediatric-drug-information/print?search=topiramat&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Williams L, Garnett WR. Clinical Pharmacology of Topiramate: A Review. Epilepsia [Internet]. 2000 [cited 2024 Feb 9];41:61–5. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1157.2000.tb02174.x

Shank RP, Maryanoff BE. Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate. CNS Neurosci Ther [Internet]. 2008 [cited 2024 Feb 9];14:120. Available from: /pmc/articles/PMC6494007/

Spritzer SD, Bravo TP, Drazkowski JF. Topiramate for Treatment in Patients with Migraine and Epilepsy. Headache. 2016;56:1081–5.

Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for Migraine Prevention in Children: A Randomized, Double-Blind, Placebo-Controlled Trial. Headache: The Journal of Head and Face Pain [Internet]. 2005 [cited 2024 Feb 9];45:1304–12. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1526-4610.2005.00262.x

Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology [Internet]. 2019 [cited 2024 Feb 9];93:500. Available from: /pmc/articles/PMC6746206/

Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: A review. Epilepsy Res. 2011;95:189–99.

Giannopoulou EZ, Gortner L, Peterlini S, Gottschling S, Yilmaz U, Meyer S. Topiramate‐induced nephrolithiasis. Clin Case Rep. 2015;3:508–9.

ROSENOW F, KNAKE S, HEBEBRAND J. Topiramate and Anorexia Nervosa. American Journal of Psychiatry. 2002;159:2112-a-2113.

Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42:387–92.

Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44:659–63.

Valproate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/valproate-pediatric-drug-information/print?search=valproat&source=panel_search_result&selectedTitle=1~150&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia [Internet]. 2008 [cited 2024 Feb 13];49:438–45. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2007.01429.x

Yeap LL, Lim KS, Lo YL, Bakar MZA, Tan CT. Valproate-induced reversible sensorineural hearing loss: a case report with serial audiometry and pharmacokinetic modelling during a valproate rechallenge. Epileptic Disorders [Internet]. 2014 [cited 2024 Feb 13];16:375–9. Available from: https://www.jle.com/fr/revues/epd/e-docs/valproate_induced_reversible_sensorineural_hearing_loss_a_case_report_with_serial_audiometry_and_pharmacokinetic_modelling_during_a_valproate_rechallenge_302328/article.phtml?tab=texte

De Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia. 2007;48:470–7.

Pigoni A, Mandolini GM, Delvecchio G, Bressi C, Soares JC, Brambilla P. A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on “Translational and Neuroscience Studies in Affective Disorders” Section Editor, Maria Nobile MD, PhD. J Affect Disord. 2020;261:277–81.

Kim SJ, Jhun BW, Lee JE, Kim K, Choi HY. A Case of Drug-Induced Interstitial Pneumonitis Caused by Valproic Acid for the Treatment of Seizure Disorders. Tuberc Respir Dis (Seoul) [Internet]. 2014 [cited 2024 Feb 13];77:145. Available from: /pmc/articles/PMC4192314/

Sanoria A, Arora R, Dokania P. Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Indian J Ophthalmol [Internet]. 2019 [cited 2024 Feb 13];67:1711. Available from: /pmc/articles/PMC6786175/

Buoli M, Serati M, Botturi A, Altamura AC. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data. Drugs R D [Internet]. 2018 [cited 2024 Feb 13];18:1. Available from: /pmc/articles/PMC5833908/

Guo HL, Jing X, Sun JY, Hu Y hui, Xu ZJ, Ni MM, et al. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Curr Pharm Des. 2019;25:343–51.

Vigabatrin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/print?search=vigabatrin&source=panel_search_result&selectedTitle=1~25&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nielsen JC, Tolbert D, Patel M, Kowalski KG, Wesche DL. Vigabatrin pediatric dosing information for refractory complex partial seizures: Results from a population dose-response analysis. Epilepsia. 2014;55:e134–8.

Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol [Internet]. 2009 [cited 2024 Feb 9];65:98. Available from: /pmc/articles/PMC2665303/

Suzuki Y. Zonisamide in West syndrome. Brain Dev [Internet]. 2001 [cited 2024 Feb 13];23:658–61. Available from: http://www.brainanddevelopment.com/article/S0387760401003011/fulltext

Zonisamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/zonisamide-pediatric-drug-information/print?search=zonisamid&source=panel_search_result&selectedTitle=1~51&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Wallander KM, Ohman I, Dahlin M. Zonisamide: Pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics. 2014;45:362–70.

Cross JH, Auvin S, Patten A, Giorgi L. Safety and tolerability of zonisamide in paediatric patients with epilepsy. European Journal of Paediatric Neurology. 2014;18:747–58.

Lehmann HC, Hartung HP, Zu Hörste GM, Kieseier BC. Plasma exchange in immune-mediated neuropathies. Curr Opin Neurol [Internet]. 2008 [cited 2024 Feb 13];21:547–54. Available from: https://journals.lww.com/co-neurology/fulltext/2008/10000/plasma_exchange_in_immune_mediated_neuropathies.7.aspx

Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol [Internet]. 2008 [cited 2024 Feb 13];21:358–65. Available from: https://journals.lww.com/co-neurology/fulltext/2008/06000/use_of_intravenous_immunoglobulin_and_plasma.23.aspx

Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol [Internet]. 2020 [cited 2024 Feb 11];20:92–9. Available from: https://pn.bmj.com/content/20/2/92

Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: An update. J Clin Apher [Internet]. 2011 [cited 2024 Feb 11];26:261–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jca.20298

Sheikh Z, Hirsch LJ. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome. Vol. 14, Frontiers in Neurology. Frontiers Media S.A.; 2023.

Therapeutic apheresis (plasma exchange or cytapheresis): Complications - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/therapeutic-apheresis-plasma-exchange-or-cytapheresis-complications

Ketogenic dietary therapies for the treatment of epilepsy - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/ketogenic-dietary-therapies-for-the-treatment-of-epilepsy/print?search=ketojenik%20diyet&source=search_result&selectedTitle=1~77&usage_type=default&display_rank=1

Freeman JM, Vining EPG, Kossoff EH, Pyzik PL, Ye X, Goodman SN. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. 2009;50:322–5.

Lambrechts DAJE, de Kinderen RJA, Vles JSH, de Louw AJA, Aldenkamp AP, Majoie HJM. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand. 2017;135:231–9.

Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7:500–6.

Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3:175–92.

G Vining EP, Professor of Neurology A, McGrogan RD JB, Hladky BSN HB, Coordinator N, Kriegler S, et al. Growth of children on the ketogenic diet. Dev Med Child Neurol [Internet]. 2002 [cited 2024 Feb 11];44:796–802. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-8749.2002.tb00769.x

Best TH, Franz DN, Gilbert DL, Nelson DP, Epstein MR. Cardiac complications in pediatric patients on the ketogenic diet. Neurology. 2000;54:2328–30.

Sampath A, Kossoff EH, Furth SL, Pyzik PL, Vining EPG. Kidney Stones and the Ketogenic Diet: Risk Factors and Prevention. http://dx.doi.org/101177/0883073807301926 [Internet]. 2007 [cited 2024 Feb 11];22:375–8. Available from: https://journals.sagepub.com/doi/10.1177/0883073807301926?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Kang HC, Chung DE, Kim DW, Kim HD. Early- and Late-onset Complications of the Ketogenic Diet for Intractable Epilepsy. Epilepsia [Internet]. 2004 [cited 2024 Feb 11];45:1116–23. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.0013-9580.2004.10004.x

Güzel O, Yılmaz U, Uysal U, Arslan N. The effect of olive oil-based ketogenic diet on serum lipid levels in epileptic children. Neurological Sciences [Internet]. 2016 [cited 2024 Feb 11];37:465–70. Available from: https://link.springer.com/article/10.1007/s10072-015-2436-2

Arya R, Shinnar S, Glauser TA. Corticosteroids for the Treatment of Infantile Spasms: A Systematic Review. [cited 2024 Feb 11]; Available from: http://jcn.sagepub.com

Hollenshead PP, Jackson CN, Cross J V, Taylor ·, Witten E, Ahmed ·, et al. Treatment modalities for infantile spasms: current considerations and evolving strategies in clinical practice. Neurological Sciences [Internet]. 2024 [cited 2024 Feb 11];45:507–14. Available from: https://doi.org/10.1007/s10072-023-07078-z

Riikonen R. Topical Review Infantile Spasms: Outcome in Clinical Studies. 2020 [cited 2024 Feb 11]; Available from: https://doi.org/10.1016/j.pediatrneurol.2020.01.015

Jain P, Sahu JK, Horn PS, Chau V, Go C, Mahood Q, et al. Treatment of children with infantile spasms: A network meta-analysis. Dev Med Child Neurol. 2022;64:1330–43.

Hancı F, Canpolat M, Kumandaş S. West Sendromu. In: Kumadaş Canpolat, editor. Temel Pediatrik Nöroloji, Tanı ve Tedavi. 1st ed. Akademisyen Kitabevi; 2022. p. 2217–28.

Cosyntropin (tetracosactide): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 13]. Available from: https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/print?search=synacthen&source=panel_search_result&selectedTitle=2~110&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Lai YC, Muscal E, Wells E, Shukla N, Eschbach K, Hyeong Lee K, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020;7:2467–74.

Kenney-Jung DL, Kahoud RJ, Vezzani A, Lafrance-Corey RG, Ho ML, Muskardin TW, et al. Super-refractory status epilepticus and febrile infection-related epilepsy syndrome treated with anakinra. [cited 2024 Feb 11]; Available from: www.mayomedicallaboratories.com/test-catalog/Overview/61511

Van Baalen A. Febrile infection-related epilepsy syndrome in childhood: A clinical review and practical approach. Seizure: European Journal of Epilepsy [Internet]. 2023 [cited 2024 Feb 11];111:1059–311. Available from: http://creativecommons.org/licenses/by/4.0/

Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus including febrile infection-related epilepsy syndrome: Statements and supporting evidence. Epilepsia. 2022;63:2840–64.

Rn Kullenberg T, Lö Fqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. [cited 2024 Feb 11]; Available from: https://academic.oup.com/rheumatology/article/55/8/1499/2566682

Anakinra: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 13]. Available from: https://www.uptodate.com/contents/anakinra-pediatric-drug-information/print?search=anakinra&source=panel_search_result&selectedTitle=2~129&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Meissner H, Cascella M. Cannabidiol (CBD). StatPearls [Internet]. 2023 [cited 2024 Feb 4]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK556048/

Cannabidiol (pharmaceutical): Pediatric drug information - UpToDate [Internet]. Available from: https://www.uptodate.com/contents/cannabidiol-pharmaceutical-pediatric-drug-information/print?search=cannabidiol&source=panel_search_result&selectedTitle=2~62&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Carlsbad CA. Epidiolex (cannabidiol) [prescribing information]. Greenwich Biosciences Inc. 2021;

Verlag K, Heinen F. NeuroKids Child Neurology Workbook: Diagnosis and Therapy. Mind Maps, Germany: W Kohlhammer GMbH Stuttgart. 2017;391–555.

Custer JW. et al. The Harriet lane handbook: mobile medicine series-expert consult. Elsevier Health Sciences; 2009. 717–1030 p.

Diazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 4]. Available from: https://www.uptodate.com/contents/diazepam-pediatric-drug-information/print?search=diazepam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Howard P, Twycross R, Shuster J, Mihalyo M, Wilcock A. Benzodiazepines. J Pain Symptom Manage. 2014;47:955–64.

Kienitz R, Kay L, Beuchat I, Gelhard S, Von Brauchitsch S, Mann · Catrin, et al. Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability Graphical Abstract Benzodiazepines in the management of seizures and status epileppcus: a review of routes of delivery, pharmacokineecs, efficacy, and tolerability. CNS Drugs [Internet]. 123AD [cited 2024 Feb 5];36. Available from: https://doi.org/10.1007/s40263-022-00940-2

Ethosuximide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 4]. Available from: https://www.uptodate.com/contents/ethosuximide-pediatric-drug-information/print?search=etos%C3%BCksimid&source=panel_search_result&selectedTitle=2~21&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, Valproic Acid and Lamotrigine in Childhood Absence Epilepsy: Initial Monotherapy Outcomes at 12 months. Epilepsia [Internet]. 2013 [cited 2024 Feb 4];54:141. Available from: /pmc/articles/PMC3538883/

Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr [Internet]. 2016 [cited 2024 Feb 5];16:48. Available from: /pmc/articles/PMC4749120/

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. The Lancet [Internet]. 2013 [cited 2024 Feb 5];381:125–32. Available from: http://www.thelancet.com/article/S0140673612611349/fulltext

Everolimus: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/everolimus-pediatric-drug-information?search=everolimus&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Felbamate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/felbamate-pediatric-drug-information?search=felbamat&source=panel_search_result&selectedTitle=2~22&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit [Internet]. 2018 [cited 2024 Feb 5];40:526–48. Available from: https://journals.lww.com/drug-monitoring/fulltext/2018/10000/therapeutic_drug_monitoring_of_antiepileptic_drugs.2.aspx

Phenytoin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/phenytoin-pediatric-drug-information/print?search=fenitoin&selectedTitle=1~147&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocritical Care 2012 17:1 [Internet]. 2012 [cited 2024 Feb 5];17:3–23. Available from: https://link.springer.com/article/10.1007/s12028-012-9695-z

Guerrini R. Epilepsy in children. The Lancet [Internet]. 2006 [cited 2024 Feb 5];367:499–524. Available from: http://www.thelancet.com/article/S0140673606681828/fulltext

Chaves J, Sander JW, Sander L. Seizure Aggravation in Idiopathic Generalized Epilepsies. Epilepsia [Internet]. 2005 [cited 2024 Feb 5];46:133–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2005.00325.x

Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D Deficiency in Children and Its Management: Review of Current Knowledge and Recommendations. Pediatrics [Internet]. 2008 [cited 2024 Feb 5];122:398–417. Available from: /pediatrics/article/122/2/398/73042/Vitamin-D-Deficiency-in-Children-and-Its

Wagner CL, Greer FR. Prevention of Rickets and Vitamin D Deficiency in Infants, Children, and Adolescents the Section on Breastfeeding and Committee on Nutrition. Pediatrics [Internet]. 2008 [cited 2024 Feb 5];122:1142–52. Available from: www.pediatrics.org/cgi/doi/10.1542/

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. Journal of Pediatrics [Internet]. 2001 [cited 2024 Feb 5];139:317–9. Available from: http://www.jpeds.com/article/S002234760118950X/fulltext

Zar T, Graeber C, Perazella MA. Reviews: Recognition, Treatment, and Prevention of Propylene Glycol Toxicity. Semin Dial [Internet]. 2007 [cited 2024 Feb 5];20:217–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1525-139X.2007.00280.x

Chandrasekaran S, Patil S, Suthar R, Attri SV, Sahu JK, Sankhyan N, et al. Hyperhomocysteinaemia in children receiving phenytoin and carbamazepine monotherapy: a cross-sectional observational study. Arch Dis Child [Internet]. 2017 [cited 2024 Feb 5];102:346–51. Available from: https://adc.bmj.com/content/102/4/346

Fosphenytoin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 10]. Available from: https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/print?search=fosfenitoin&source=panel_search_result&selectedTitle=2~50&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Morton LD. Clinical experience with fosphenytoin in children. J Child Neurol. 1998;13.

Shenoi RP, Timm N, Jones B, Neville K, Foster J, Houck C, et al. Drugs used to treat pediatric emergencies. Pediatrics [Internet]. 2020 [cited 2024 Feb 11];145:288–92. Available from: /pediatrics/article/145/1/e20193450/36970/Drugs-Used-to-Treat-Pediatric-Emergencies

Phenobarbital: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/phenobarbital-pediatric-drug-information/print?search=fenobarbital&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Vasquez A, Gaínza-Lein M, Sánchez Fernández I, Abend NS, Anderson A, Brenton JN, et al. Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research Centers. Pediatr Neurol [Internet]. 2018 [cited 2024 Feb 5];86:33–41. Available from: http://www.pedneur.com/article/S0887899418302315/fulltext

Tobias JD. Pentobarbital for Sedation During Mechanical Ventilation in the Pediatric ICU Patient. 2000.

Fenfluramine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/fenfluramine-pediatric-drug-information/print?search=fenfluramine&source=panel_search_result&selectedTitle=2~22&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Wirrell EC. Treatment of Dravet Syndrome. Canadian Journal of Neurological Sciences. 2016;43:S13–8.

Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatr Neurol [Internet]. 2017 [cited 2024 Feb 5];68:18-34.e3. Available from: http://www.pedneur.com/article/S0887899416310372/fulltext

Gabapentin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/print?search=gabapentin&selectedTitle=1~146&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Beauvais K, Disson-Dautriche A, Jacquin A, Antoniol C, Martin ML. Gabapentin-induced encephalopathy. Clinical Neurophysiology. 2015;126:845–6.

Hui CH, Ka-Chun Leung J, Shek-Kwan Chang R, Shea YF. Reversible dysphagia due to gabapentin-induced jaw myoclonus. 2019 [cited 2024 Feb 5]; Available from: www.cmj.org

Bilgir O, Alan M, Bilgir F, Kebapılar L, Yksel A, Ar Yıldız Y", et al. Gabapentin-Induced Rhabdomyolysis in a Patient with Diabetic Neuropathy. [cited 2024 Feb 5]; Available from: http://www.naika.or.jp/imindex.html

Choi MS, Jeon H, Kim HS, Jang BH, Lee YH, Park HS, et al. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodialysis International [Internet]. 2017 [cited 2024 Feb 5];21:E4–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/hdi.12458

Hampton Z, Shahrestani N, Little A. Gabapentin-induced Facial Myoclonus in the Setting of Acute on Chronic Kidney Disease. [cited 2024 Feb 5]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s050,020882s035,021129s033lbl.pdf

Parsons KA, Derkits ME. Visual hallucinations associated with gabapentin use. American Journal of Health-System Pharmacy [Internet]. 2016 [cited 2024 Feb 5];73:631–4. Available from: https://dx.doi.org/10.2146/ajhp150136

Rohman L, Hebron A. Acute dystonic reaction caused by gabapentin. Journal of Emergency Medicine [Internet]. 2014 [cited 2024 Feb 5];46:e89. Available from: http://www.jem-journal.com/article/S0736467913009347/fulltext

Souzdalnitski D, Chang AK, Guirguis M. Chorea in a Chronic Pain Patient Using Gabapentin. Ochsner J [Internet]. 2014 [cited 2024 Feb 5];14:276. Available from: /pmc/articles/PMC4052599/

Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. European Neuropsychopharmacology. 2017;27:1185–215.

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) | FDA [Internet]. [cited 2024 Feb 9]. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin

Norton JW, Professor of Neurology A. Gabapentin Withdrawal Syndrome [Internet]. Vol. 24, Clinical Neuropharmacology. 2001. Available from: http://journals.lww.com/clinicalneuropharmbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo

Immune globulin (Intravenous, subcutaneous, and intramuscular): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramuscular-pediatric-drug-information/print?search=imm%C3%BCn%20globulin%20intraven%C3%B6z&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA [Internet]. 2021 [cited 2024 Feb 6];325:855–64. Available from: https://jamanetwork.com/journals/jama/fullarticle/2776054

Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P, et al. Challenges in the treatment of convulsive status epilepticus. 2017 [cited 2024 Feb 11]; Available from: http://dx.doi.org/10.1016/j.seizure.2017.02.015

Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9.

Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–77.

Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia. 2015;56:915–23.

Bertilsson L. Clinical Pharmacokinetics of Carbamazepine. Clin Pharmacokinet. 1978;3:128–43.

Carbamazepine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/carbamazepine-pediatric-drug-information/print?search=karbamazepin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Tutor-Crespo MJ, Hermida J, Tutor JC. Relative Proportions of Serum Carbamazepine and its Pharmacologically Active 10,11-Epoxy Derivative: Effect of Polytherapy and Renal Insufficiency. Ups J Med Sci [Internet]. 2008 [cited 2024 Feb 12];113:171–80. Available from: https://www.tandfonline.com/doi/abs/10.3109/2000-1967-225

Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions. Neurology [Internet]. 2017 [cited 2024 Feb 12];88:2183. Available from: /pmc/articles/PMC5467955/

Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Tran E, Berger R, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clin Pharmacol Ther [Internet]. 2013 [cited 2024 Feb 12];94:324. Available from: /pmc/articles/PMC3748365/

Godwin SA, Burton JH, Gerardo CJ, Hatten BW, MacE SE, Silvers SM, et al. Clinical Policy: Procedural Sedation and Analgesia in the Emergency Department. Ann Emerg Med [Internet]. 2014 [cited 2024 Feb 5];63:247-258.e18. Available from: http://www.annemergmed.com/article/S0196064413014893/fulltext

Green SM, Roback MG, Kennedy RM, Krauss B. Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update. Ann Emerg Med [Internet]. 2011 [cited 2024 Feb 5];57:449–61. Available from: http://www.annemergmed.com/article/S0196064410018275/fulltext

Ferguson CL, Beckett RD. Intranasal ketamine for treatment of acute pain in pediatrics: A systematic review. Pediatr Emerg Care [Internet]. 2020 [cited 2024 Feb 5];36:476–81. Available from: https://journals.lww.com/pec-online/fulltext/2020/08000/intranasal_ketamine_for_treatment_of_acute_pain_in.22.aspx

Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial. JAMA Pediatr [Internet]. 2019 [cited 2024 Feb 5];173:140. Available from: /pmc/articles/PMC6439599/

Alletag MJ, Auerbach MA, Baum CR. Ketamine, propofol, and ketofol use for pediatric sedation. Pediatr Emerg Care. 2012;28:1391–8.

Ketamine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/ketamine-pediatric-drug-information?search=ketamin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Quibell R, Fallon M, Mihalyo M, Twycross R, Wilcock A. Ketamine*. J Pain Symptom Manage [Internet]. 2015 [cited 2024 Feb 5];50:268–78. Available from: http://www.jpsmjournal.com/article/S0885392415002729/fulltext

Isojarvi J, Gidal BE, Chung S, Wechsler RT. Optimizing clobazam treatment in patients with Lennox–Gastaut syndrome. Epilepsy and Behavior [Internet]. 2018 [cited 2024 Feb 5];78:149–54. Available from: http://www.epilepsybehavior.com/article/S1525505017307217/fulltext

Perry MS, Bailey L, Malik S, Gilson C, Kotecha A, Hernandez A. Clobazam for the treatment of intractable epilepsy in children. J Child Neurol [Internet]. 2013 [cited 2024 Feb 5];28:34–9. Available from: https://journals.sagepub.com/doi/10.1177/0883073812461943?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Clobazam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 5]. Available from: https://www.uptodate.com/contents/clobazam-pediatric-drug-information/print?search=klobazam&source=panel_search_result&selectedTitle=2~27&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kamas T, Serdaro E, Yılmaz O, Aydın Kılıç B, Polat BG, Erdo I, et al. The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. Epilepsy Res [Internet]. 2022 [cited 2024 Feb 5];184:106963. Available from: https://doi.org/10.1016/j.eplepsyres.2022.106963

Ng Y tze, Collins SD. Clobazam. Neurotherapeutics [Internet]. 2007 [cited 2024 Feb 5];4:138. Available from: /pmc/articles/PMC7479695/

Clonazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/clonazepam-pediatric-drug-information/print?search=klonazepam&usage_type=panel&kp_tab=drug_pediatric&source=panel_search_result&selectedTitle=2~131&display_rank=1

Lamotrigine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/lamotrigine-pediatric-drug-information?search=lamotrijin&source=panel_search_result&selectedTitle=2~139&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

French JA, Perucca E, Sander JW, Bergfeldt L, Baulac M, Auerbach DS, et al. FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsia Open [Internet]. 2021 [cited 2024 Feb 6];6:45. Available from: /pmc/articles/PMC7918301/

Lacosamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/lacosamide-pediatric-drug-information?search=lakozamid&source=panel_search_result&selectedTitle=2~35&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia [Internet]. 2017 [cited 2024 Feb 6];58:933–50. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13716

Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, et al. Lacosamide in pediatric and adult patients: Comparison of efficacy and safety. [cited 2024 Feb 6]; Available from: http://dx.doi.org/10.1016/j.seizure.2012.12.009

Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia. 2010;51:958–67.

Newey CR, Le NM, Ahrens C, Sahota P, Hantus S. The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill. Neurocrit Care [Internet]. 2017 [cited 2024 Feb 6];26:273–9. Available from: https://link.springer.com/article/10.1007/s12028-016-0322-2

Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M, Smeyers-Durá P, Herranz-Fernández JL, Ibáñez-Micó S, et al. Efficacy and Tolerability of Lacosamide in the Concomitant Treatment of 130 Patients Under 16 Years of Age with Refractory Epilepsy: A Prospective, Open-Label, Observational, Multicenter Study in Spain. Drugs R D [Internet]. 2012 [cited 2024 Feb 6];12:187. Available from: /pmc/articles/PMC3585895/

Levetiracetam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/levetiracetam-pediatric-drug-information?search=levetirasetam&source=panel_search_result&selectedTitle=2~115&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kochanek PM, Tasker RC, Carney N, Totten AM, Adelson PD, Selden NR, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary. Clin Neurosurg [Internet]. 2019 [cited 2024 Feb 6];84:1169–78. Available from: https://journals.lww.com/neurosurgery/fulltext/2019/06000/guidelines_for_the_management_of_pediatric_severe.2.aspx

Chau K, Yong J, Ismail K, Griffith N, Liu M, Makris A. Levetiracetam-induced severe acute granulomatous interstitial nephritis. Clin Kidney J [Internet]. 2012 [cited 2024 Feb 6];5:234. Available from: /pmc/articles/PMC4400501/

Kim J, Shin JW. Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. Epileptic Disorders [Internet]. 2017 [cited 2024 Feb 6];19:104–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1684/epd.2017.0889

Bonastre MTT, Muñoz SP, Boza FM, Gumà Padró J. Neutropenia Secondary to Exposure to Levetiracetam. https://doi.org/105301/tj5000312 [Internet]. 2015 [cited 2024 Feb 6];101:e145–6. Available from: https://journals.sagepub.com/doi/10.5301/tj.5000312?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Yim SH, Choi YH, Heo K, Cho KH. A case of dyskinesia after levetiracetam administration. BMC Neurol [Internet]. 2019 [cited 2024 Feb 6];19. Available from: /pmc/articles/PMC6862831/

Lee YY, Ko JH, Chung WH. Acute generalized exanthematous pustulosis induced by levetiracetam. Int J Dermatol. 2014;53.

Bayram AK, Canpolat M, Çinar SL, Tahan F, Gumus H, Kumandaş S, et al. Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient. Journal of Emergency Medicine [Internet]. 2016 [cited 2024 Feb 6];50:e61–6. Available from: http://www.jem-journal.com/article/S0736467915010525/fulltext

Jayashankar S, Munakomi S, Sayeerajan V, Kafle P, Chaudhary P, Thingujam J, et al. Open Peer Review Case Report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient [version 1; peer review: 2 approved]. 2019 [cited 2024 Feb 6]; Available from: https://doi.org/10.12688/f1000research.18198.1

Van Den Broek MPH, Rademaker CMA, Van Straaten HLM, Huitema ADR, Toet MC, De Vries LS, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed [Internet]. 2013 [cited 2024 Feb 6];98:F341–5. Available from: https://fn.bmj.com/content/98/4/F341

Malingré MM, Van Rooij LGM, Rademaker CMA, Toet MC, Ververs TFFT, Van Kesteren C, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr [Internet]. 2006 [cited 2024 Feb 6];165:598–604. Available from: https://link.springer.com/article/10.1007/s00431-006-0136-x

Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-pediatric-drug-information/print?search=lidokain&selectedTitle=1~125&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Favié LMA, Huitema ADR, van den Broek MPH, Rademaker CMA, de Haan TR, van Straaten HLM, et al. Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen. Br J Clin Pharmacol. 2020;86:75–84.

Weeke LC, Toet MC, Van Rooij LGM, Groenendaal F, Boylan GB, Pressler RM, et al. Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. Epilepsia [Internet]. 2016 [cited 2024 Feb 6];57:233–42. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13286

Pressler RM, Abend NS, Auvin S, Boylan G, Brigo F, Cilio MR, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations—Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia. 2023;64:2550–70.

Lorazepam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/print?search=lorazepam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Methylprednisolone: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 6]. Available from: https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/print?search=metilprednizolon&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Early Acute Management in Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionals. J Spinal Cord Med [Internet]. 2008 [cited 2024 Feb 6];31:403. Available from: /pmc/articles/PMC2582434/

Johannesdottir SA, Horváth-Puh́o E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study. JAMA Intern Med [Internet]. 2013 [cited 2024 Feb 6];173:743–52. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1673744

Midazolam: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 7]. Available from: https://www.uptodate.com/contents/midazolam-pediatric-drug-information/print?search=midazolam&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Mula M. The safety and tolerability of intranasal midazolam in epilepsy. Expert Rev Neurother. 2014;14:735–40.

Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42:380–6.

van der Vossen AC, van Nuland M, Ista EG, de Wildt SN, Hanff LM. Oral lorazepam can be substituted for intravenous midazolam when weaning paediatric intensive care patients off sedation. Acta Paediatr [Internet]. 2018 [cited 2024 Feb 9];107:1594. Available from: /pmc/articles/PMC6120549/

Mayel M, Nejad MA, Khabaz MS, Bazrafshani MS, Mohajeri E. Intranasal midazolam sedation as an effective sedation route in pediatric patients for radiologic imaging in the emergency ward: A single-blind randomized trial. Turk J Emerg Med [Internet]. 2020 [cited 2024 Feb 9];20:168. Available from: /pmc/articles/PMC7549517/

Warrington SE, Collier HK, Himebauch AS, Wolfe HA. Evaluation of IV to enteral benzodiazepine conversion calculations in a pediatric intensive care setting. Pediatric Critical Care Medicine [Internet]. 2018 [cited 2024 Feb 9];19:E569–75. Available from: https://journals.lww.com/pccmjournal/fulltext/2018/11000/evaluation_of_iv_to_enteral_benzodiazepine.19.aspx

Fantacci C, Fabrizio GC, Ferrara P, Franceschi F, Chiaretti A. IN drug administration for procedural sedation in children admitted to Pediatric Emergency Room.

Ancora G, Lago P, Garetti E, Merazzi D, Savant Levet P, Bellieni CV, et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. Acta Paediatr [Internet]. 2019 [cited 2024 Feb 9];108:208–17. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/apa.14606

Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit [Internet]. 2000. Available from: http://journals.lww.com/ccmjournal

Oxcarbazepine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/oxcarbazepine-pediatric-drug-information/print?search=okskarbazepin&source=panel_search_result&selectedTitle=2~126&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Martinez W, Ingenito A, Blakeslee M, Barkley GL, McCague K, D’Souza J. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy and Behavior. 2006;9:448–56.

Buggy Y, Layton D, Fogg C, Shakir SAW. Safety profile of oxcarbazepine: Results from a prescription-event monitoring study. Epilepsia. 2010;51:818–29.

Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol [Internet]. 2005 [cited 2024 Feb 9];33:337–44. Available from: http://www.pedneur.com/article/S0887899405002687/fulltext

Piña-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65:1370–5.

Kothare S V., Mostofi N, Khurana DS, Mohsem B, Melvin JJ, Hardison HH, et al. Oxcarbazepine Therapy in Very Young Children: A Single-Center Clinical Experience. Pediatr Neurol [Internet]. 2006 [cited 2024 Feb 9];35:173–6. Available from: http://www.pedneur.com/article/S0887899406001883/fulltext

Berghuis B, van der Palen J, de Haan GJ, Lindhout D, Koeleman BPC, Sander JW, et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017;58:1227–33.

Piracetam: International drug information (concise) - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/piracetam-international-drug-information-concise/print?search=pirasetam&source=panel_search_result&selectedTitle=1~9&usage_type=panel&kp_tab=drug_international&display_rank=1

Dai AI, Demiryürek AT. Effectiveness Oral Theophylline, Piracetam, and Iron Treatments in Children With Simple Breath-Holding Spells. J Child Neurol [Internet]. 2020 [cited 2024 Feb 9];35:25–30. Available from: https://journals.sagepub.com/doi/10.1177/0883073819871854?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Sawires H, Botrous O. Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells. Eur J Pediatr [Internet]. 2012 [cited 2024 Feb 9];171:1063–7. Available from: https://link.springer.com/article/10.1007/s00431-012-1680-1

Baugh RF, Basura GJ, Ishii LE, Schwartz SR, Drumheller CM, Burkholder R, et al. Clinical Practice Guideline: Bell’s Palsy. Otolaryngology–Head and Neck Surgery [Internet]. 2013 [cited 2024 Feb 9];149:S1–27. Available from: https://onlinelibrary.wiley.com/doi/full/10.1177/0194599813505967

Yoo HW, Yoon L, Kim HY, Kwak MJ, Park KH, Bae MH, et al. Comparison of conservative therapy and steroid therapy for Bell’s palsy in children. Korean J Pediatr [Internet]. 2018 [cited 2024 Feb 9];61:332. Available from: /pmc/articles/PMC6212712/

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology [Internet]. 2021 [cited 2024 Feb 9];96:114. Available from: /pmc/articles/PMC7884987/

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev [Internet]. 2016 [cited 2024 Feb 9];2016. Available from: /pmc/articles/PMC8580515/

Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology [Internet]. 2016 [cited 2024 Feb 9];86:465. Available from: /pmc/articles/PMC4773944/

Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014;122:455–64.

Prednisolone (systemic): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/prednisolone-systemic-pediatric-drug-information/print?search=prednizolon&source=panel_search_result&selectedTitle=2~145&usage_type=panel&showDrugLabel=true&display_rank=2

Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4.

Pregabalin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/pregabalin-pediatric-drug-information/print?search=pregabalin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, et al. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J [Internet]. 2016 [cited 2024 Feb 9];14. Available from: /pmc/articles/PMC4967327/

Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, et al. Practice parameter: Therapies for essential tremor: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008–20.

Primidone: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/primidone-pediatric-drug-information/print?search=primidon&source=panel_search_result&selectedTitle=2~52&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology 2012 260:3 [Internet]. 2012 [cited 2024 Feb 9];260:714–40. Available from: https://link.springer.com/article/10.1007/s00415-012-6628-x

Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol. 2011;10:148–61.

Propofol: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/propofol-pediatric-drug-information/print?search=propofol&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Prabhakar H, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev [Internet]. 2017 [cited 2024 Feb 9];2017. Available from: /pmc/articles/PMC6464235/

Vespasiano M, Finkelstein M, Kurachek S. Propofol Sedation: Intensivists’ Experience With 7304 Cases in a Children’s Hospital. Pediatrics [Internet]. 2007 [cited 2024 Feb 9];120:e1411–7. Available from: /pediatrics/article/120/6/e1411/70538/Propofol-Sedation-Intensivists-Experience-With

Srinivasan M, Turmelle M, Depalma LM, Mao J, Carlson DW. Procedural Sedation for Diagnostic Imaging in Children by Pediatric Hospitalists using Propofol: Analysis of the Nature, Frequency, and Predictors of Adverse Events and Interventions. J Pediatr. 2012;160:801-806.e1.

Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med [Internet]. 2013 [cited 2024 Feb 9];41:263–306. Available from: https://journals.lww.com/ccmjournal/fulltext/2013/01000/clinical_practice_guidelines_for_the_management_of.29.aspx

Holtkamp M. Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults. Drugs [Internet]. 2018 [cited 2024 Feb 9];78. Available from: https://doi.org/10.1007/s40265-017-0859-1

Pyridoxine-Dependent Epilepsy - Symptoms, Causes, Treatment | NORD [Internet]. [cited 2024 Feb 9]. Available from: https://rarediseases.org/rare-diseases/pyridoxine-dependent-epilepsy/

Coughlin CR, Tseng LA, Abdenur JE, Ashmore C, Boemer F, Bok LA, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2021;44:178–92.

Stockler S, Plecko B, Gospe SM, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104:48–60.

Vitamin B6 (pyridoxine): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/vitamin-b6-pyridoxine-pediatric-drug-information/print?search=pridoksin&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Morrow LE, Wear RE, Schuller D, Malesker M. Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [Internet]. 2006 [cited 2024 Feb 9];26:1529–32. Available from: https://onlinelibrary.wiley.com/doi/full/10.1592/phco.26.10.1529

Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand [Internet]. 2016 [cited 2024 Feb 12];133:160. Available from: /pmc/articles/PMC4738453/

Yamamoto T, Gil-Nagel A, Wheless JW, Kim JH, Wechsler RT. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence. Vol. 136, Epilepsy and Behavior. Academic Press Inc.; 2022.

Perampanel: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/perampanel-pediatric-drug-information/print?search=perampanel&source=panel_search_result&selectedTitle=2~18&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nepal G, Shing YK, Yadav JK, Rehrig JH, Ojha R, Huang DY, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis. Acta Neurol Scand [Internet]. 2020 [cited 2024 Feb 13];142:449–59. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ane.13291

Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol [Internet]. 2016 [cited 2024 Feb 13];73:1342–8. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2553834

Rituximab (intravenous) including biosimilars: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-pediatric-drug-information/print?search=rituximab&selectedTitle=1~147&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88.

Rufinamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/rufinamide-pediatric-drug-information/print?search=rufinamid&source=panel_search_result&selectedTitle=2~9&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Kluger G, Haberlandt E, Kurlemann G, Ernst JP, Runge U, Schneider F, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy & Behavior. 2010;17:546–8.

Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia. 2009;50:1899–909.

Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia [Internet]. 2011 [cited 2024 Feb 9];52:234–42. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2010.02729.x

Löscher W, Klein P. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs [Internet]. 2021 [cited 2024 Feb 12];35:935. Available from: /pmc/articles/PMC8408078/

Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer [Internet]. 2011 [cited 2024 Feb 9];57:1018–24. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.23124

Sun B, Han T, Wang Y, Gao Q, Cui J, Shen W. Sirolimus as a Potential Treatment for Sturge-Weber Syndrome. Journal of Craniofacial Surgery [Internet]. 2021 [cited 2024 Feb 9];32:257–60. Available from: https://journals.lww.com/jcraniofacialsurgery/fulltext/2021/02000/sirolimus_as_a_potential_treatment_for.60.aspx

Sirolimus (conventional): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/sirolimus-conventional-pediatric-drug-information/print?search=sirolimus&selectedTitle=1~145&usage_type=panel&display_rank=1&kp_tab=drug_pediatric&source=panel_search_result

Stiripentol: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/stiripentol-pediatric-drug-information/print?search=stiripentol&source=panel_search_result&selectedTitle=2~12&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Fisher JL. The anticonvulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology [Internet]. 2009 [cited 2024 Feb 9];56:190. Available from: /pmc/articles/PMC2665930/

Chiron C, Marchand MC, Tran A, Rey E, D’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. Lancet [Internet]. 2000 [cited 2024 Feb 9];356:1638–42. Available from: http://www.thelancet.com/article/S0140673600031573/fulltext

Milburn-McNulty P, Panebianco M, Marson AG. Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev [Internet]. 2021 [cited 2024 Feb 9];2021. Available from: /pmc/articles/PMC8459749/

Tacke M, Borggraefe I, Gerstl L, Heinen F, Vill K, Bonfert M, et al. Effects of Levetiracetam and Sulthiame on EEG in benign epilepsy with centrotemporal spikes: A randomized controlled trial. Seizure. 2018;56:115–20.

Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo-controlled study. Epilepsia. 2000;41:1284–8.

Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249–51.

Tiagabine: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/tiagabine-pediatric-drug-information/print?search=tiagabin&source=panel_search_result&selectedTitle=1~26&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Uthman BM, Rowan AJ, Ahmann PA, Leppik IE, Schachter SC, Sommerville KW, et al. Tiagabine for complex partial seizures: A randomized, add-on, dose- response trial. Arch Neurol. 1998;55:56–62.

Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84:940–5.

Cantarín-Extremera V, Jiménez-Legido M, Duat-Rodríguez A, García-Fernández M, Valentina Ortiz-Cabrera N, Luz Ruiz-Falcó-Rojas M, et al. Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients. 2020 [cited 2024 Feb 11]; Available from: https://doi.org/10.1016/j.jneuroim.2019.577142

Stredny CM, Case S, Sansevere AJ, Son M, Henderson L, Gorman MP. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). [cited 2024 Feb 11]; Available from: https://us.sagepub.com/en-us/nam/open-access-at-sage

Girardin ML, Flamand T, Roignot O, Abi Warde MT, Mutschler V, Voulleminot P, et al. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia. 2023;64:e87–92.

Tocilizumab (including biosimilars): Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/tocilizumab-including-biosimilars-pediatric-drug-information/print?search=tocilizumab&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Leung E, Crass RL, J Jorgensen SC, Raybardhan S, Langford BJ, Justin Moore W, et al. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin Pharmacokinet [Internet]. 123AD [cited 2024 Feb 11];61:11. Available from: https://doi.org/10.1007/s40262-021-01092-0

Topiramate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 12]. Available from: https://www.uptodate.com/contents/topiramate-pediatric-drug-information/print?search=topiramat&source=panel_search_result&selectedTitle=2~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Williams L, Garnett WR. Clinical Pharmacology of Topiramate: A Review. Epilepsia [Internet]. 2000 [cited 2024 Feb 9];41:61–5. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1157.2000.tb02174.x

Shank RP, Maryanoff BE. Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate. CNS Neurosci Ther [Internet]. 2008 [cited 2024 Feb 9];14:120. Available from: /pmc/articles/PMC6494007/

Spritzer SD, Bravo TP, Drazkowski JF. Topiramate for Treatment in Patients with Migraine and Epilepsy. Headache. 2016;56:1081–5.

Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for Migraine Prevention in Children: A Randomized, Double-Blind, Placebo-Controlled Trial. Headache: The Journal of Head and Face Pain [Internet]. 2005 [cited 2024 Feb 9];45:1304–12. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1526-4610.2005.00262.x

Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology [Internet]. 2019 [cited 2024 Feb 9];93:500. Available from: /pmc/articles/PMC6746206/

Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: A review. Epilepsy Res. 2011;95:189–99.

Giannopoulou EZ, Gortner L, Peterlini S, Gottschling S, Yilmaz U, Meyer S. Topiramate‐induced nephrolithiasis. Clin Case Rep. 2015;3:508–9.

ROSENOW F, KNAKE S, HEBEBRAND J. Topiramate and Anorexia Nervosa. American Journal of Psychiatry. 2002;159:2112-a-2113.

Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia. 2001;42:387–92.

Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44:659–63.

Valproate: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/valproate-pediatric-drug-information/print?search=valproat&source=panel_search_result&selectedTitle=1~150&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia [Internet]. 2008 [cited 2024 Feb 13];49:438–45. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2007.01429.x

Yeap LL, Lim KS, Lo YL, Bakar MZA, Tan CT. Valproate-induced reversible sensorineural hearing loss: a case report with serial audiometry and pharmacokinetic modelling during a valproate rechallenge. Epileptic Disorders [Internet]. 2014 [cited 2024 Feb 13];16:375–9. Available from: https://www.jle.com/fr/revues/epd/e-docs/valproate_induced_reversible_sensorineural_hearing_loss_a_case_report_with_serial_audiometry_and_pharmacokinetic_modelling_during_a_valproate_rechallenge_302328/article.phtml?tab=texte

De Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia. 2007;48:470–7.

Pigoni A, Mandolini GM, Delvecchio G, Bressi C, Soares JC, Brambilla P. A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on “Translational and Neuroscience Studies in Affective Disorders” Section Editor, Maria Nobile MD, PhD. J Affect Disord. 2020;261:277–81.

Kim SJ, Jhun BW, Lee JE, Kim K, Choi HY. A Case of Drug-Induced Interstitial Pneumonitis Caused by Valproic Acid for the Treatment of Seizure Disorders. Tuberc Respir Dis (Seoul) [Internet]. 2014 [cited 2024 Feb 13];77:145. Available from: /pmc/articles/PMC4192314/

Sanoria A, Arora R, Dokania P. Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Indian J Ophthalmol [Internet]. 2019 [cited 2024 Feb 13];67:1711. Available from: /pmc/articles/PMC6786175/

Buoli M, Serati M, Botturi A, Altamura AC. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data. Drugs R D [Internet]. 2018 [cited 2024 Feb 13];18:1. Available from: /pmc/articles/PMC5833908/

Guo HL, Jing X, Sun JY, Hu Y hui, Xu ZJ, Ni MM, et al. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Curr Pharm Des. 2019;25:343–51.

Vigabatrin: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/vigabatrin-pediatric-drug-information/print?search=vigabatrin&source=panel_search_result&selectedTitle=1~25&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Nielsen JC, Tolbert D, Patel M, Kowalski KG, Wesche DL. Vigabatrin pediatric dosing information for refractory complex partial seizures: Results from a population dose-response analysis. Epilepsia. 2014;55:e134–8.

Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol [Internet]. 2009 [cited 2024 Feb 9];65:98. Available from: /pmc/articles/PMC2665303/

Suzuki Y. Zonisamide in West syndrome. Brain Dev [Internet]. 2001 [cited 2024 Feb 13];23:658–61. Available from: http://www.brainanddevelopment.com/article/S0387760401003011/fulltext

Zonisamide: Pediatric drug information - UpToDate [Internet]. [cited 2024 Feb 9]. Available from: https://www.uptodate.com/contents/zonisamide-pediatric-drug-information/print?search=zonisamid&source=panel_search_result&selectedTitle=1~51&usage_type=panel&kp_tab=drug_pediatric&display_rank=1

Wallander KM, Ohman I, Dahlin M. Zonisamide: Pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics. 2014;45:362–70.

Cross JH, Auvin S, Patten A, Giorgi L. Safety and tolerability of zonisamide in paediatric patients with epilepsy. European Journal of Paediatric Neurology. 2014;18:747–58.

Lehmann HC, Hartung HP, Zu Hörste GM, Kieseier BC. Plasma exchange in immune-mediated neuropathies. Curr Opin Neurol [Internet]. 2008 [cited 2024 Feb 13];21:547–54. Available from: https://journals.lww.com/co-neurology/fulltext/2008/10000/plasma_exchange_in_immune_mediated_neuropathies.7.aspx

Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol [Internet]. 2008 [cited 2024 Feb 13];21:358–65. Available from: https://journals.lww.com/co-neurology/fulltext/2008/06000/use_of_intravenous_immunoglobulin_and_plasma.23.aspx

Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol [Internet]. 2020 [cited 2024 Feb 11];20:92–9. Available from: https://pn.bmj.com/content/20/2/92

Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: An update. J Clin Apher [Internet]. 2011 [cited 2024 Feb 11];26:261–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jca.20298

Sheikh Z, Hirsch LJ. A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome. Vol. 14, Frontiers in Neurology. Frontiers Media S.A.; 2023.

Therapeutic apheresis (plasma exchange or cytapheresis): Complications - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/therapeutic-apheresis-plasma-exchange-or-cytapheresis-complications

Ketogenic dietary therapies for the treatment of epilepsy - UpToDate [Internet]. [cited 2024 Feb 11]. Available from: https://www.uptodate.com/contents/ketogenic-dietary-therapies-for-the-treatment-of-epilepsy/print?search=ketojenik%20diyet&source=search_result&selectedTitle=1~77&usage_type=default&display_rank=1

Freeman JM, Vining EPG, Kossoff EH, Pyzik PL, Ye X, Goodman SN. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. 2009;50:322–5.

Lambrechts DAJE, de Kinderen RJA, Vles JSH, de Louw AJA, Aldenkamp AP, Majoie HJM. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand. 2017;135:231–9.

Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7:500–6.

Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3:175–92.

G Vining EP, Professor of Neurology A, McGrogan RD JB, Hladky BSN HB, Coordinator N, Kriegler S, et al. Growth of children on the ketogenic diet. Dev Med Child Neurol [Internet]. 2002 [cited 2024 Feb 11];44:796–802. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1469-8749.2002.tb00769.x

Best TH, Franz DN, Gilbert DL, Nelson DP, Epstein MR. Cardiac complications in pediatric patients on the ketogenic diet. Neurology. 2000;54:2328–30.

Sampath A, Kossoff EH, Furth SL, Pyzik PL, Vining EPG. Kidney Stones and the Ketogenic Diet: Risk Factors and Prevention. http://dx.doi.org/101177/0883073807301926 [Internet]. 2007 [cited 2024 Feb 11];22:375–8. Available from: https://journals.sagepub.com/doi/10.1177/0883073807301926?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Kang HC, Chung DE, Kim DW, Kim HD. Early- and Late-onset Complications of the Ketogenic Diet for Intractable Epilepsy. Epilepsia [Internet]. 2004 [cited 2024 Feb 11];45:1116–23. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.0013-9580.2004.10004.x

Güzel O, Yılmaz U, Uysal U, Arslan N. The effect of olive oil-based ketogenic diet on serum lipid levels in epileptic children. Neurological Sciences [Internet]. 2016 [cited 2024 Feb 11];37:465–70. Available from: https://link.springer.com/article/10.1007/s10072-015-2436-2